ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer.

Aileen Patricia SzczepanskiZibo ZhaoTori SosnowskiYoung Ah GooElizabeth Thomas BartomLu Wang

Published in: Genome medicine (2020)

Collectively, this study provides a mechanistic insight into the oncogenic function of BRD4/ASXL3/BAP1 epigenetic axis at active chromatin enhancers in SCLC-A subtype, as well as a potential new therapeutic option that could become more effective in treating SCLC patients with a biomarker of ASXL3-highly expressed SCLC cells.

Keyphrases

small cell lung cancer
transcription factor
gene expression
induced apoptosis
dna methylation
cell cycle arrest
dna damage
binding protein
signaling pathway
endoplasmic reticulum stress
cell death
brain metastases